Premium
Effect of clindamycin treatment on vaginal inflammatory markers in pregnant women with bacterial vaginosis and a positive fetal fibronectin test
Author(s) -
DiazCueto Laura,
DominguezLopez Pablo,
TenaAlavez Gilberto,
CuicaFlores Adrian,
RosalesOrtiz Sergio,
ArechavaletaVelasco Fabian
Publication year - 2009
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2009.06.015
Subject(s) - bacterial vaginosis , medicine , fetal fibronectin , asymptomatic , clindamycin , obstetrics , prospective cohort study , pregnancy , vagina , gynecology , gestation , antibiotics , surgery , preterm labor , microbiology and biotechnology , biology , genetics
Objective To compare the levels of interleukin (IL)‐1β, IL‐6, and matrix metalloproteinase (MMP)‐8 in the vaginal secretions of pregnant women with a positive fetal fibronectin (fFN) test result with or without asymptomatic bacterial vaginosis (BV) before and after treatment with oral clindamycin. Methods A prospective cohort study was conducted among 43 pregnant women with a positive fFN test result. All patients were treated with clindamycin, and the pre‐ and post‐treatment levels of IL‐1β, IL‐6, and MMP‐8 were compared. Results Before treatment, levels of IL‐1β and MMP‐8 were significantly higher in women with BV compared with women without BV ( P < 0.05). Vaginal levels of IL‐1β and IL‐6, but not MMP‐8, decreased after treatment in pregnant women with BV. Conclusions The inability of clindamycin to decrease MMP‐8 vaginal levels may explain why it is ineffective in reducing preterm birth in pregnant women with positive fFN and BV.